AI支援ロボット血栓摘出術のための血管内モデルと有効性指標に関する提言
A Position Statement on Endovascular Models and Effectiveness Metrics for Mechanical Thrombectomy Navigation, on behalf of the Stakeholder Taskforce for AI-assisted Robotic Thrombectomy (START)
脳卒中治療のためのAI支援ロボット血栓摘出術の開発と検証に向け、専門家会議で有効性指標の標準化と4種類のテストベッド（in silico, in vitro, ex vivo, in vivo）の役割を定義した提言。
詳しい要約
1. どんなもの？
2. 先行研究と比べてどこがすごい？
3. 技術・手法の肝は？
4. どうやって有効だと検証した？
5. 議論はある？
6. 次に読むべき論文は？
※ AIが要旨から生成した要約です。正確性は原文をご確認ください。
著者: Harry Robertshaw, Anna Barnes, Phil Blakelock, Raphael Blanc, Robert Crossley, Rebecca Fahrig, Ameer E. Hassan, Benjamin Jackson, Lennart Karstensen, Neelam Kaur, Markus Kowarschik, Jeremy Lynch, Franziska Mathis-Ullrich, Dwight Meglan, Vitor Mendes Pereira, Mouloud Ourak, Matteo Pantano, S. M. Hadi Sadati, Alice Taylor-Gee, Tom Vercauteren, Phil White, Alejandro Granados, Thomas C. Booth
分類: cs.RO
原文アブストラクト
While we are making progress in overcoming infectious diseases and cancer; one of the major medical challenges of the mid-21st century will be the rising prevalence of stroke. Large vessels occlusions are especially debilitating, yet effective treatment (needed within hours to achieve best outcomes) remains limited due to geography. One solution for improving timely access to mechanical thrombectomy in geographically diverse populations is the deployment of robotic surgical systems. Artificial intelligence (AI) assistance may enable the upskilling of operators in this emerging therapeutic delivery approach. Our aim was to establish consensus frameworks for developing and validating AI-assisted robots for thrombectomy. Objectives included standardizing effectiveness metrics and defining reference testbeds across in silico, in vitro, ex vivo, and in vivo environments. To achieve this, we convened experts in neurointervention, robotics, data science, health economics, policy, statistics, and patient advocacy. Consensus was built through an incubator day, a Delphi process, and a final Position Statement. We identified that the four essential testbed environments each had distinct validation roles. Realism requirements vary: simpler testbeds should include realistic vessel anatomy compatible with guidewire and catheter use, while standard testbeds should incorporate deformable vessels. More advanced testbeds should include blood flow, pulsatility, and disease features. There are two macro-classes of effectiveness metrics: one for in silico, in vitro, and ex vivo stages focusing on technical navigation, and another for in vivo stages, focused on clinical outcomes. Patient safety is central to this technology's development. One requisite patient safety task needed now is to correlate in vitro measurements to in vivo complications.
関連論文
- 片手補助：単一チャネル内視鏡的粘膜下層剥離術における牽引のための連続体ロボット把持器医療ロボティクス
- 脳血管内治療における臨床医とAIの協働：自律性スペクトラムにわたるロボットナビゲーションのCopilot支援モードに関するin-vitroユーザー研究医療ロボティクス
- 低悪性度脾外傷の止血に向けた監督付き自律双腕吸引・焼灼システム医療ロボティクス
- 言語条件付き行動クローニングによる自律内視鏡ガイダンス医療ロボティクス
- MCP-Net：ロボットガイドワイヤ操作のためのリアルタイム冠動脈認識ネットワークとトポロジー解析医療ロボティクス
- 手術フェーズ認識と視覚追従を統合した自律腹腔鏡制御フレームワーク医療ロボティクス
